Palvella Therapeutics, Inc. (PVLA)
NASDAQ: PVLA · Real-Time Price · USD
157.24
+9.47 (6.41%)
At close: Jul 17, 2026, 4:00 PM EDT
159.16
+1.92 (1.22%)
After-hours: Jul 17, 2026, 7:52 PM EDT
Palvella Therapeutics Employees
Palvella Therapeutics had 29 employees as of December 31, 2025. The number of employees increased by 15 or 107.14% compared to the previous year.
Employees
29
Change (1Y)
15
Growth (1Y)
107.14%
Revenue / Employee
n/a
Profits / Employee
-$1,699,897
Market Cap
2.26B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 29 | 15 | 107.14% |
| Dec 31, 2024 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| Iovance Biotherapeutics | 975 |
| Agios Pharmaceuticals | 540 |
| Vericel | 398 |
| Nurix Therapeutics | 317 |
| Biohaven | 274 |
| Mesoblast | 81 |
| Mineralys Therapeutics | 76 |
PVLA News
- 19 days ago - Palvella Therapeutics appoints Savara CEO Matt Pauls to board - TheFly
- 19 days ago - Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors - GlobeNewsWire
- 20 days ago - Palvella submits first rolling new drug application to FDA for Qtorin - TheFly
- 20 days ago - Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations - GlobeNewsWire
- 27 days ago - FDA grants rolling review to Palvella Therapeutics Qtorin rapamycin - TheFly
- 27 days ago - FDA Grants Rolling Review of Palvella's QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations - GlobeNewsWire
- 5 weeks ago - Palvella Therapeutics Transcript: AGM 2026 - Transcripts
- 5 weeks ago - Palvella Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts